




Belgo-Indian symposium



on Antimycobacterial drug development

16 September 2024, 9 am-18 pm

Location: Brussels, Université Libre de Bruxelles (ULB)

Qualified researchers will present keynote lectures and Belgian PhD students or postdoc will be able to present short communications.

The inscription is free but mandatory through the following link (closed on September 16th, 2024) :

https://docs.google.com/forms/d/e/1FAIpQLSdc8gh3jqmaF6DY5Tqqxi5QSLvZEIXywyOfXUYGrI6-ISANSw/viewform?usp=sf_link

Program divided in 4 sessions:

- New antimycobacterial and antimicrobial compounds in view
- New mycobacterial targets in view
- New drug regimens in view
- New antimycobacterial drug assessments in view

Among the qualified managers making an oral presentation:

- Prof. Jayanta Haldar (JNCASR, Bangalore, India) on « Vancomycin analogues in the pipeline of antimicrobial drug development »
- Prof. Alain Baulard (Institut Pasteur de Lille, France) on « Rewiring *M.tuberculosis* to reverse antibiotic resistance: Alpibectir from bench to bedside »
- Prof. Leen Rigouts (Institute of Tropical Medicine, Antwerp, Belgium) on “Genetic variants across phylogenetic lineages of *Mycobacterium tuberculosis* complex may cause resistance in drug-naïve populations”.
- Prof. Gilles Berger (Université Libre de Bruxelles) on « Exploring transition metal complexes for human diseases »
- Prof. Véronique Fontaine (Université Libre de Bruxelles) on “Why to target GroEL1 and PDIM biosynthesis to fight *M. tuberculosis*”

This event is subsidized by Belspo (Project TBNewvan of Prof. Véronique Fontaine, Belgium and Prof. Jayanta Haldar, India).